Vistagen reports promising PH284 nasal spray study By Investing.com

Vistagen reports promising PH284 nasal spray study By Investingcom

SOUTH SAN FRANCISCO – Vistagen Therapeutics (VTGN), a clinical-stage neuroscience company with a market…

www.investing.com

More posts

Jamie Dimon on tariffs, geopolitics—and the misery facing the bottom 20% of U.S. earners

March 20, 2025
Stock Market Today: Stocks Enjoy a Fed Day Relief Rally

March 20, 2025
Volatility Shares launching Solana futures ETFs March 20

March 20, 2025
PCI Express 7.0’s blazing speeds are nearly here, but PCIe 6 is still vapor

March 20, 2025